Valuation Novo Nordisk A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 19/09/2024 BST			5-day change	1st Jan Change
898.20 ^DKK	+1.81%		-1.75%	+28.66%

09-18	Hims & Hers offers compounded Wegovy for $99 a month to select professions	RE
09-18	NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases	CI

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	909,347	986,612	1,674,992	2,118,803	3,112,331	3,910,736	-	-
Change	-	8.5%	69.77%	26.5%	46.89%	25.65%	-	-
Enterprise Value (EV) ¹	898,355	984,211	1,684,152	2,121,013	3,109,107	3,924,841	3,901,669	3,869,293
Change	-	9.56%	71.12%	25.94%	46.59%	26.24%	-0.59%	-0.83%
P/E ratio	23.6x	23.7x	35.4x	38.4x	37.5x	38.8x	30.5x	25.6x
PBR	15.8x	15.8x	24x	25.6x	29.4x	27.2x	20.2x	15.7x
PEG	-	2.38x	2.3x	2.2x	0.7x	1.8x	1.1x	1.3x
Capitalization / Revenue	7.45x	7.77x	11.9x	12x	13.4x	13.5x	11.2x	9.64x
EV / Revenue	7.36x	7.75x	12x	12x	13.4x	13.5x	11.2x	9.53x
EV / EBITDA	15.5x	16.4x	26x	25.8x	27.8x	27.6x	22.1x	18.6x
EV / EBIT	17.1x	18.2x	28.7x	28.4x	30.3x	30.6x	24.2x	20.4x
EV / FCF	26.1x	34.5x	57.4x	37x	45.5x	52.8x	41.4x	32.7x
FCF Yield	3.83%	2.9%	1.74%	2.7%	2.2%	1.9%	2.41%	3.05%
Dividend per Share ²	4.175	4.55	5.2	6.2	9.4	11.4	15.03	17.6
Rate of return	2.16%	2.13%	1.41%	1.32%	1.35%	1.29%	1.7%	1.99%
EPS ²	8.19	9.005	10.37	12.22	18.62	22.71	28.89	34.4
Distribution rate	51%	50.5%	50.1%	50.7%	50.5%	50.2%	52%	51.2%
Net sales ¹	122,021	126,946	140,800	176,954	232,261	290,081	348,988	405,888
EBITDA ¹	58,144	59,879	64,669	82,171	111,987	142,456	176,414	207,955
EBIT ¹	52,483	54,126	58,644	74,809	102,574	128,373	161,428	189,856
Net income ¹	38,951	42,138	47,757	55,525	83,683	101,797	127,816	149,148
Net Debt ¹	-10,992	-2,401	9,160	2,210	-3,224	14,105	-9,067	-41,443
Reference price ²	193.32	213.32	367.50	469.00	698.10	882.20	882.20	882.20
Nbr of stocks (in thousands)	4,703,720	4,624,923	4,557,801	4,517,704	4,458,288	4,432,936	-	-
Announcement Date	05/02/20	03/02/21	02/02/22	01/02/23	31/01/24	-	-	-

¹DKK in Million²DKK

Estimates

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E ratio	EV / Sales	EV / EBITDA	Yield (Y)	Capi. ($)
NOVO NORDISK A/S	38.84x	13.53x	27.55x	+1.29%	583B
ELI LILLY AND COMPANY	58.35x	18.08x	43.97x	+0.57%	816B
JOHNSON & JOHNSON	21.27x	4.6x	13.01x	+2.82%	402B
ABBVIE INC.	37.55x	7.12x	15.38x	+3.23%	342B
MERCK & CO., INC.	15.82x	5.02x	11.5x	+2.59%	300B
ROCHE HOLDING AG	16.1x	3.8x	9.83x	+3.67%	255B
ASTRAZENECA PLC	28.05x	5.05x	15.11x	+1.98%	243B
NOVARTIS AG	21.51x	4.96x	12.55x	+3.26%	235B
AMGEN INC.	51.29x	6.9x	12.08x	+2.76%	179B
PFIZER, INC.	21.85x	3.73x	10.08x	+5.60%	169B
Average	31.06x	7.28x	17.11x	+2.78%	352.32B
Weighted average by Cap.	35.54x	9.55x	22.38x	+2.23%